NASDAQ:ONCO

Onconetix (ONCO) Stock Price, News & Analysis

Onconetix logo
$3.15 +0.15 (+5.00%)
Closing price 04:00 PM Eastern
Extended Trading
$3.12 -0.02 (-0.79%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Onconetix Stock (NASDAQ:ONCO)

Advanced

Key Stats

Today's Range
$3.04
▼
$3.22
50-Day Range
$2.91
▼
$11.10
52-Week Range
$2.76
▼
$1,610.00
Volume
64,657 shs
Average Volume
166,882 shs
Market Capitalization
$1.86 million
P/E Ratio
0.00
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk.

Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets.

Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024. The company has also been associated with ENTADFI, a prescription treatment for benign prostatic hyperplasia, though its current commercial status is not described here.

AI Generated. May Contain Errors.

Onconetix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

ONCO MarketRank™: 
0.888118415785 of 5 stars

Onconetix scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Onconetix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Onconetix has only been the subject of 1 research reports in the past 90 days.

  • Read more about Onconetix's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Onconetix is 0.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.88.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Onconetix is 0.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.66.

  • Price to Book Value per Share Ratio

    Onconetix has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    163.14% of the float of Onconetix has been sold short.
  • Short Interest Ratio / Days to Cover

    Onconetix has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Onconetix has recently increased by 145.62%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Onconetix does not currently pay a dividend.

  • Dividend Growth

    Onconetix does not have a long track record of dividend growth.

  • News Sentiment

    Onconetix has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Onconetix this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for ONCO on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Onconetix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.27% of the stock of Onconetix is held by insiders.

  • Percentage Held by Institutions

    23.89% of the stock of Onconetix is held by institutions.

  • Read more about Onconetix's insider trading history.
Receive ONCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ONCO Stock News Headlines

Realbotix Provides Update on Nasdaq Listing Timeline
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Headlines

ONCO Stock Analysis - Frequently Asked Questions

Onconetix's stock was trading at $780.00 at the start of the year. Since then, ONCO stock has decreased by 99.6% and is now trading at $3.1250.

Onconetix, Inc. (NASDAQ:ONCO) released its quarterly earnings data on Monday, November, 16th. The company reported ($76.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($45,050.00) by $44,973.99. The company had revenue of $102.88 thousand for the quarter, compared to the consensus estimate of $103 thousand. Onconetix had a negative trailing twelve-month return on equity of 91.95% and a negative net margin of 1,575.89%.

Onconetix shares reverse split before market open on Friday, May 22nd 2026.The 1-10 reverse split was announced on Tuesday, May 19th 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 21st 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Onconetix (ONCO) raised $20 million in an IPO on Thursday, February 17th 2022. The company issued 2,222,222 shares at a price of $8.00-$10.00 per share.

Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/16/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ONCO
Previous Symbol
NASDAQ:ONCO
CIK
1782107
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$2,481.20
Trailing P/E Ratio
0.00
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.03 million
Net Margins
-1,575.89%
Pretax Margin
-1,575.89%
Return on Equity
-91.95%
Return on Assets
-53.76%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.21
Quick Ratio
2.14

Sales & Book Value

Annual Sales
$810 thousand
Price / Sales
2.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5,052.88 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
590,000
Free Float
587,000
Market Cap
$1.86 million
Optionable
N/A
Beta
2.62
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:ONCO) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners